Abstract 414: Aberrant DNA methylation and expression of mRNA in EGFR-mutant lung cancer cell line with long-term exposure to gefitinib
Hideki Terai(Kitasato Institute Hospital), Tomoko Betsuyaku(Tokyo Medical University), Makoto Nishino(Keio University), Tetsuo Tani(Keio University), Keiko Ohgino(Keio University), Aoi Kuroda(Keio University), Kota Ishioka(Keio University), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Katsuhiko Naoki(Broad Institute), Takashi Sato(Kitasato University), Masayoshi Miyawaki(Keio University), Ayano Ohashi(Keio University), Kenzo Soejima(Keio University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101